ALR Technologies SG Ltd. Files 20-F/A Amendment

TL;DR

ALR Tech filed an amendment to its 2023 annual report, updating financials and confirming name change.

AI Summary

ALR Technologies SG Ltd. filed an amendment (20-F/A) on July 1, 2024, to its annual report for the fiscal year ending December 31, 2023. The filing indicates a change in company name from ALR Technologies SG Pte. Ltd. on May 20, 2022. Financial data for the years 2020, 2021, 2022, and 2023 are referenced, including common stock, additional paid-in capital, and retained earnings.

Why It Matters

This filing provides updated financial information and regulatory compliance for ALR Technologies SG Ltd., which is crucial for investors and stakeholders to assess the company's financial health and status.

Risk Assessment

Risk Level: low — This is a routine amendment filing for an annual report, not indicating any immediate financial distress or significant new risks.

Key Numbers

• 2023 — Fiscal Year End (The primary reporting period covered by the amendment.)
• 2022-05-20 — Name Change Date (Date when the company changed its name.)

Key Players & Entities

• ALR Technologies SG Ltd. (company) — Filer of the 20-F/A amendment
• ALR Technologies SG Pte. Ltd. (company) — Former company name
• 2023-12-31 (date) — End of the reporting period
• 20240701 (date) — Filing date of the amendment

FAQ

Key Financial Figures

• $ — erwise noted herein, all references to "$," "dollars" or "U.S. dollars" are to th
• $120,108,400 — ure. We had an accumulated deficit of $120,108,400, $112,633,886 and $102,015,077 at Decem
• $112,633,886 — an accumulated deficit of $120,108,400, $112,633,886 and $102,015,077 at December 31, 2023 2
• $102,015,077 — ficit of $120,108,400, $112,633,886 and $102,015,077 at December 31, 2023 2022 and 2021, res
• $7,474,514 — respectively. We recorded net losses of $7,474,514, $10,618,809 and $8,443,315 for the yea
• $10,618,809 — . We recorded net losses of $7,474,514, $10,618,809 and $8,443,315 for the years ended Dece
• $8,443,315 — t losses of $7,474,514, $10,618,809 and $8,443,315 for the years ended December 31, 2023,

Filing Documents

• alrt_20fa.htm (20-F/A) — 2064KB
• ex12_1.htm (EX-12.1) — 13KB
• ex12_2.htm (EX-12.2) — 13KB
• ex13_1.htm (EX-13.1) — 4KB
• image_001.jpg (GRAPHIC) — 3KB
• alrt-001.jpg (GRAPHIC) — 268KB
• alrt-002.jpg (GRAPHIC) — 137KB
• 0001903596-24-000395.txt ( ) — 8783KB
• alrt-20231231.xsd (EX-101.SCH) — 69KB
• alrt-20231231_cal.xml (EX-101.CAL) — 46KB
• alrt-20231231_def.xml (EX-101.DEF) — 112KB
• alrt-20231231_lab.xml (EX-101.LAB) — 304KB
• alrt-20231231_pre.xml (EX-101.PRE) — 233KB
• alrt_20fa_htm.xml (XML) — 1660KB

Quantitative and Qualitative Disclosures About Market

Quantitative and Qualitative Disclosures About Market Risk 58 Item 12.

Description of Securities Other than Equity Securities

Description of Securities Other than Equity Securities 58 PART II Item 13. Defaults, Dividend Arrearages and Delinquencies 58 Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 58 Item 15.

Controls and Procedures

Controls and Procedures 58 Item 16. [Reserved] 60 Item 16A. Audit committee financial expert 60 Item 16B. Code of Ethics 60 Item 16C. Principal Accountant Fees and Services 60 Item 16D. Exemptions from the Listing Standards for Audit Committees 61 Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 61 Item 16F. Change in Registrant's Certifying Accountant 61 Item 16G. Corporate Governance 61 Item 16H. Mine Safety Disclosure 61 Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 61 Item 16J. Cybersecurity Risk Management, Strategy, Governance, and Incident Disclosure 61 PART III Item 17.

Financial Statements

Financial Statements 61 Item 18.

Financial Statements

Financial Statements 62 Item 19. Exhibits 63

SIGNATURES

SIGNATURES 64 INTRODUCTION References in this Annual Report on Form 20-F ("Annual Report") to the "Company," "we," "us," or "our," unless the context otherwise requires, refer to ALR Technologies SG Ltd., a Singapore public company limited by shares, together with its consolidated subsidiaries. References in this Annual Report to "ALR Singapore" refer to ALR Technologies SG Ltd. References in this Annual Report to "ALR Nevada" refer to ALR Technologies Inc., a Nevada corporation. References in this Annual Report to "ALR Canada" refer to Canada Diabetes Solution Centre Inc., a Canadian corporation. Unless otherwise noted herein, all references to "$," "dollars" or "U.S. dollars" are to the currency of the United

Forward-looking Statements

Forward-looking Statements This Annual Report and documents incorporated by reference herein contain forward-looking statements. Many of the forward-looking statements contained in this Annual Report can be identified by the use of words such as "anticipate," "believe," "could," "expect," "should," "plan," "intend," "will," "estimate" and "potential," among others, or the negatives thereof. Such forward-looking are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking These risks and uncertainties include factors relating to: our operation as a development-stage company with limited operating history and a history of operating losses; our need for substantial additional funding to continue the development of our product candidates before we can expect to become profitable from sales of our products and the possibility that we may be unable to raise additional capital when needed; the outcome of our review of strategic options and of any action that we may pursue as a result of such review; the chance that we may become exposed to costly and damaging liability claims resulting from the testing of our product candidates in the clinic or in the commercial stage; uncertainty surrounding whether any of our product candidates will receive regulatory approval, where required, before they can be commercialized; where any of our product candidates obtain regulatory approval, those product candidates being enacted and futur

financial statements, and shareholders could lose all or part of their investment in our ordinary shares

financial statements, and shareholders could lose all or part of their investment in our ordinary shares. We have experienced net losses for each of the past three years, and we could experience additional losses and have difficulty achieving profitability in the future. We had an accumulated deficit of $120,108,400, $112,633,886 and $102,015,077 at December 31, 2023 2022 and 2021, respectively. We recorded net losses of $7,474,514, $10,618,809 and $8,443,315 for the years ended December 31, 2023, 2022, and 2021, respectively. In order to achieve profitability, we must control our costs and increase net revenue through new sales. Failure to increase our net revenue and decrease our costs could cause our share price to decline and could have material adverse effect on our business, financial condition, and results of operations. 5 We could need to raise additional capital in the future, and if we are unable to secure adequate funds on terms acceptable to us, we could be unable to execute our business plan. To remain competitive, we must continue to make significant investments in the development of our products, in obtaining regulatory clearances to introduce our product into new markets, in the expansion of our sales and marketing activities, and in the expansion of our operating and management infrastructure as we increase sales domestically and internationally. If cash generated from our operations is insufficient to fund such growth, we could be required to raise additional funds through the issuance of equity or debt securities in the public or private markets, or through a collaborative arrangement or sale of assets. Additional financing opportunities may not be available to us, or if available, may not be on favorable terms. The availability of financing opportunities will depend, in part, on market conditions, and the outlook for our business. Any future issuance of equity securities or securities convertible into equity securities could result in s

View Full Filing

View this 20-F/A filing on SEC EDGAR